Aarhus University Seal

Nickel-Catalyzed Innovation in Drug Labeling

In a major advancement for pharmaceutical science, researchers from iNANO, in collaboration with AstraZeneca and The Arctic University of Norway (UiT), have developed a novel method for synthesizing isotopically labeled alkyl aryl ketones.

The researchers demonstrated the efficiency and versatility of the nicel-catalyzed carbonylative cross-coupling method synthesizing alkyl aryl ketones. The team optimized reaction conditions and achieved high yields for a variety of ketone products including pharmaceutically relevant compounds. This new reaction provides a streamlined approach for late-stage isotope labeling, offering significant potential in drug synthesis and radiolabeling applications. Angew. Chem. Int. Ed. 2024, e202412247

The study published in Angewandte Chemie reveals an efficient way to incorporate stable (13C) and radioactive carbon isotopes (14C) directly into pharmaceutical compounds. The methodology employs nickel catalysts and aryl boronic acids, combined with redox-activated alkyl carboxylic esters under mild conditions, to create isotopically labeled ketones, a key structure found in many drugs. This approach could aid the production of labeled pharmaceuticals, particularly in late-stage isotope labeling, which is critical for drug development.

The use of COgen and SilaCOgen allow easy switching between stable and radioactive isotopes and marks a significant advantage for this reaction. Radiolabeled compounds, which are crucial for tracing a drug's behavior, are notoriously difficult and expensive to produce. This method offers a simpler solution for incorporating carbon isotopes, reducing reliance on complex radiolabel precursors.

The researchers conducted detailed Density Functional Theory (DFT) calculations and experimental validation, confirming that the process involves carbon-centered radical formation and a CO insertion step—crucial for producing the ketone products.

These advancements allow pharmaceutical companies to generate essential metabolism data in drug development, providing insights into how drugs behave in the body and their potential environmental impact. The technique also supports labeling for clinical pharmacokinetic and pharmacodynamic studies.

The method has already been successfully applied to pharmaceuticals such as bupropion and droperidol, illustrating its versatility across different drug types.

About the research

Study type:
Experimental Chemistry

External funding:
KHH and SG thank the Research Council of Norway (No. 300769) and Sigma2 (No. nn9330k and nn4654k). KSM, KHH and SG thank the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No. 859910. VE thanks the Danish National Research Foundation (No. DNRF118)

Conflicts of interest:
Troels Skrydstrup is a co-owner of SyTracks a/s, which commercializes the COware® technology.

Link to the scientific article:
https://doi.org/10.1002/anie.202412247

Kim S. Mühlfenzl, Vitus J. Enemærke, Sahil Gahlawat, Peter I. Golbækdal, Nikoline Munksgaard-Ottosen, Karoline T. Neumann, Kathrin H. Hopmann, Per-Ola Norrby, Charles S. Elmore and Troels Skrydstrup.

Contact information:
Professor Troels Skydstrup
Aarhus University
Interdisciplinary Nanoscience Center (iNANO)
Department of Chemistry
Email: ts@chem.au.dk